Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394067 | 0.95 | SLC29A1 (0.39) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL15214781 | 0.92 | SLC29A1 (0.36) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL12112160 | 0.89 | PDE10A (0.48) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL16123784 | 0.86 | SLC29A1 (0.46) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL15214751 | 0.85 | PDE10A (0.51) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL13394148 | 0.85 | SLC29A1 (0.47) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL15214749 | 0.85 | ADORA2A (0.47) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL13394054 | 0.85 | SLC29A1 (0.47) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL15214750 | 0.85 | ADORA2A (0.41) | SLC29A1ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL13394123 | 0.85 | HDAC6 (0.43) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2014149084-A2 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | SLC29A1 2701/4885ADORA2A 4578/4885PI4KA 2269/4885 |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | SLC29A1 2701/4885ADORA2A 4578/4885PI4KA 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.